Clinical TrialJun 5, 2026, 11:32 AM
Teva AUSTEDO Data Shows 60-71% Patient QoL Improvement in HD Chorea
AI Summary
Teva Pharmaceuticals announced new real-world survey data for AUSTEDO and AUSTEDO XR, demonstrating significant improvements in quality of life for patients with Huntington's disease (HD) chorea and their caregivers. The study revealed that 60-71% of patients reported improved quality of life due to better movement control, and 74% saw improvements in chorea movements. Caregivers also experienced reduced impact on their daily lives, with 77% reporting improvements in social life and emotional wellbeing.
Key Highlights
- 60-71% of patients reported improved quality of life after AUSTEDO/AUSTEDO XR treatment.
- 74% of patients reported improvements in chorea movements since initiating treatment.
- Over 85% of patients reported improvements in daily activities and social lives.
- 77% of caregivers reported improvements in social life and emotional wellbeing.
- Over 68% of patients initially reported HD chorea interfering with social life or emotional wellbeing.
- Up to 83% of caregivers initially noted impact on their own daily lives due to caregiving.
Price Impact
More from TEVA